FNCH
Finch Therapeutics Group, Inc.
Key Financials
Net Income
$-74754000
↑ 34.8%
Revenue
$107000
↓ 87.6%
Operating Income
$-83861000
↑ 27.5%
Total Assets
$55.4M
↓ 66.0%
Total Liabilities
$32.5M
↓ 51.7%
Shareholders' Equity
$22.9M
↓ 76.1%
EPS (Diluted)
$-46.59
↓ 1841.3%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 11/12/2024 | View on SEC |
| EFFECT | 11/4/2024 | View on SEC |
| POS AM | 11/1/2024 | View on SEC |
| S-8 POS | 11/1/2024 | View on SEC |
| S-8 POS | 11/1/2024 | View on SEC |
| S-8 POS | 11/1/2024 | View on SEC |
| 25 | 10/31/2024 | View on SEC |
| 8-K | 10/21/2024 | View on SEC |
| 10-Q | 8/13/2024 | View on SEC |
| 8-K | 8/12/2024 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FNCH |
| Company Name | Finch Therapeutics Group, Inc. |
| CIK | 1733257 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | OTC |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-229-6499 |